New Breast Cancer Treatment Highlights the Potential of ADCs
Earlier this year, the FDA approved a new targeted chemotherapy, Datroway (datopotamab deruxtecan) for adults with unresectable or metastatic hormone receptor (HR)-positive, HER2 negative breast
September 10, 2025
No Comments